Efficacy and Limitations of rCBF-SPECT in the Diagnosis of Alzheimer's Disease With Amyloid-PET.
This study aimed to assess efficacy and limitations of regional cerebral blood flow imaging using single-photon emission computed tomography (rCBF-SPECT) in the diagnosis of Alzheimer's disease (AD) with amyloid-positron emission tomography (amyloid-PET). Thirteen patients, who underwent both rCBF-SPECT and amyloid-PET after clinical diagnosis of AD or mild cognitive impairment, were retrospectively identified. The rCBF-SPECTs were classified into 4 grades, from typical AD pattern to no AD pattern of hypoperfusion; amyloid-beta (Aβ) positivity was assessed by amyloid-PET. Four patients were categorized into a typical AD pattern on rCBF-SPECT, and all were Aβ+. The other 9 patients did not exhibit a typical AD pattern; however, 4 were Aβ+. The Mini-Mental State Examination score and Clinical Dementia Rating scale were not significantly different between Aβ+ and Aβ- patients. A typical AD pattern on rCBF-SPECT can reflect Aβ+; however, if not, rCBF-SPECT has a limitation to predict amyloid pathology.
['Takahashi|Miwako|M|', 'Tada|Tomoko|T|', 'Nakamura|Tomomi|T|', 'Koyama|Keitaro|K|', 'Momose|Toshimitsu|T|0000-0002-7566-400X']
D000368:Aged D000369:Aged, 80 and over D000544:Alzheimer Disease D016229:Amyloid beta-Peptides D000814:Aniline Compounds D002560:Cerebrovascular Circulation D060825:Cognitive Dysfunction D005026:Ethylene Glycols D005260:Female D006801:Humans D008297:Male D064847:Multimodal Imaging D049268:Positron-Emission Tomography D012189:Retrospective Studies D015899:Tomography, Emission-Computed, Single-Photon
amyloid-PET mild cognitive impairment Alzheimer’s disease florbetapir-PET regional cerebral blood flow SPECT